United States Patent 4,303,651 Scope, Claims, and Patent Landscape for Heparin Fragments (14–18 Sugar Units) with Selective Anticoagulation
Executive summary: U.S. Patent 4,303,651 claims specific heparin/heparan sulfate-derived fragments defined by (i) length (14–18 sugar units), (ii) a signature disaccharide motif (L-iduronosyl-2-O-sulfate–N-sulfo-D-glucosamine-6-O-sulfate), and (iii) a positional constraint for an unsulfated L-iduronic acid located 3–5 residues from the unreducing terminus, followed by either N-sulfo-D-glucosamine sulfate or (optionally sulfated/unsulfated) N-acetyl-glucosamine. Dependent claims cover pharmaceutical compositions for preventative or therapeutic arterial thrombosis, including water and an ointment dosage form. The practical landscape is that this patent targets a narrow structural “fingerprint” rather than generic “low molecular weight heparin” (LMWH) concepts, raising the bar for infringement and creating a frequent design-around path based on altering fragment length, sulfation pattern, and/or the position of unsulfated iduronic acid.
No additional patent-claim content or full claim-set is provided beyond claims 1–6, so the analysis below is limited to scope, construction logic, and the competitive freedom space those constraints imply.
What does US Patent 4,303,651 claim for heparin fragments (14–18 sugar units)?
Core covered subject matter:
Claims 1–2 cover heparin fragments defined by structural formula constraints that converge to a small set of allowable oligomers. Claims 3–4 cover pharmaceutical compositions containing those fragments for arterial thrombosis (prevention and treatment). Claims 5–6 narrow the carrier and dosage form.
Claim 1: “main component” disaccharide + positional unsulfated iduronic acid
Claim 1 limitation stack (infringement-relevant):
- Fragment size: 14–18 sugar units.
- Main disaccharide unit:
- L-iduronosyl-2-O-sulfate
- linked to N-sulfo-D-glucosamine-6-O-sulfate
- Positional constraint:
- unsulfated L-iduronic acid located 3–5 sugar units from the unreducing terminus
- Following residue identity: the residue after that unsulfated iduronic acid is selected from:
- N-sulfo-D-glucosamine sulfate
- N-acetyl-glucosamine in sulfated or unsulfated form
Interpretation mechanics likely used in litigation:
- The phrase “main component” implies the fragment composition is dominated by the disaccharide motif described. In practice, this pushes defendants toward fragment populations where the motif is not dominant (or where alternative motifs dominate).
- The “3–5 sugar units from the unreducing terminal” is a regio-positional requirement, not just “contains unsulfated iduronic acid.”
- The “followed by” condition ties the iduronic residue’s adjacent neighbor identity and sulfation state.
Claim 2: explicit oligomer topology (U-G)n – I – G – (U-G)m
Claim 2 limitation stack:
- Fragment has repeating block structure: (U-G)n – I – G – (U-G)m
- n ∈ {1, 2} and m ∈ {5, 6}
- I = unsulfated L-iduronic acid
- U = L-iduronic acid-2-O-sulfate
- G = N-sulfo-D-glucosamine-6-O-sulfate
What this means for practical claim scope:
- The claim expresses a constrained topology: an internal unsulfated iduronic acid (I) embedded between N-sulfoglucosamine units.
- By fixing n and m options, the claim effectively constrains the number of (U-G) repeats, which correlates directly with total sugar units.
Claim 1 vs Claim 2: overlap and different infringement proofs
- Claim 1 is feature/sequence-content based (dominant disaccharide + position of unsulfated iduronic acid + neighbor identity options).
- Claim 2 is formula/topology based (explicit block structure with n and m ranges).
- A given accused fragment preparation may be tested against both: Claim 2 provides a cleaner match if topology aligns; Claim 1 can still capture compositions that satisfy the “main component” and positional rules even if the exact repeat pattern is argued differently.
How broad are the “14–18 sugar units” and sulfation-position limits in claim 1?
Length: 14–18 sugar units is narrow enough to exclude many common “low molecular weight” categories that are often broader in commercial distributions. It is still wide enough to cover multiple possible oligomer compositions, creating room for mixture distributions if a sample includes fragments within that size range.
Positional unsulfated iduronic acid (3–5 from unreducing terminus):
- This is the most “design-around” relevant element because it forces a specific regiochemical placement of an unsulfated iduronic acid.
- Many manufacturing or depolymerization approaches (controlled enzymatic digestion, chemical cleavage, or fractionation) can generate iduronic acid residues at various positions. The claim narrows to a subset.
Neighbor residue requirement:
- After the unsulfated iduronic acid, the next residue must be N-sulfo-D-glucosamine sulfate or N-acetyl-glucosamine (sulfated or unsulfated).
- That adjacency condition can be altered by process choices that shift glycosylation/sulfation patterns or by further chemical or enzymatic modifications.
What pharmaceutical compositions are covered for arterial thrombosis prevention or treatment?
Claim 3 and claim 4 share the same therapeutic framing and different fragment specificity proof routes depending on whether the fragment is described as claim 1’s motif/positional rule (claim 3) or claim 2’s block formula (claim 4).
Claim 3: composition + claim 1 fragment definition
- Contains heparin fragments of 14–18 sugar units
- “Main component” is the specified disaccharide
- Unsulfated iduronic acid is 3–5 units from unreducing terminal
- Followed by specified residue set
- Carrier included
- Indication: preventative treatment or treatment of arterial thrombosis
Scope implication: claim 3 ties both structure and route/product use (arterial thrombosis) to the same composition.
Claim 4: composition + claim 2 fragment topology
- Contains fragments of formula: (U-G)n – I – G – (U-G)m
- n = 1 or 2; m = 5 or 6
- Includes unsulfated iduronic acid (I) and defined sulfated building blocks (U, G)
- Amount sufficient for anticoagulation activity
- Carrier included
- Indication: preventative treatment or treatment of arterial thrombosis
Scope implication: claim 4 likely covers the same active fragment family as claim 3 when the block topology is translated into positional content, but it is easier to match structurally if the topology is explicitly analyzable.
What carriers and dosage forms are protected (water and ointment)?
Claim 5: water carrier
- If claim 3 or 4 fragment criteria are met, carrier being water is an extra limitation.
- This is a narrower product form than “any pharmaceutical carrier,” but it can still matter for competitive formulations where the carrier selection is deliberate (e.g., solvents/vehicle systems vs aqueous formulations).
Claim 6: ointment dosage form
- Requires the composition to be an ointment.
- This narrows field-of-use and product form: even if the active fragment is present, a non-ointment formulation may avoid claim 6 while still possibly implicating claims 3–4 depending on whether the claims are asserted against “compositions” generally.
How many distinct structural configurations does claim 2 allow, and how does that affect infringement risk?
With n ∈ {1,2} and m ∈ {5,6}, claim 2 permits four combinations:
- n=1, m=5
- n=1, m=6
- n=2, m=5
- n=2, m=6
Each configuration changes total repeat count, which correlates with fragment length and the number of sulfated disaccharide units versus the embedded unsulfated iduronic acid.
Infringement consequence:
- Defendants can attempt to avoid claim 2 by producing fragments with repeat counts outside the allowed set, even if they share the same basic building blocks (U, I, G).
- If the active fragment preparation is heterogeneous, plaintiffs will typically seek evidence that infringing structures are present at sufficient abundance or that the claim is met by the fragment population defined for the product.
How does US 4,303,651 compare with broader “low molecular weight heparin” IP?
Key distinction:
U.S. 4,303,651 is not claiming “low molecular weight heparin” by mass or general depolymerization category. It claims specific structural features (fragment length window, a dominant disaccharide motif, and a positional unsulfated iduronic acid rule) and, in claim 2, an explicit block structural formula.
Practical consequence for freedom-to-operate:
- A competitor can sometimes clear around if it makes fragments that:
- are outside the 14–18 sugar unit window, or
- place unsulfated iduronic acid residues outside 3–5 from unreducing terminus, or
- alter the adjacency after the unsulfated iduronic acid so the next residue fails the allowed identity set, or
- uses a formulation vehicle not matching specific narrower claims (water for claim 5; ointment for claim 6).
What patent landscape markers matter for 4,303,651 competitors (design-arounds and likely claim-challenging levers)?
The claims do not depend on a dosing regimen, but they do depend heavily on molecular structure and fragment composition analytics. That makes the landscape turn on:
- Analytical comparability
- If the accused material’s fragment profile is shown to shift out of the structural constraints, infringement weakens.
- Process-linked structural outcomes
- Fragment generation and fractionation can change unsulfated iduronic acid positioning and sulfation patterns.
- Formulation carve-outs
- Avoiding claim 6 (ointment) and claim 5 (water carrier) can still leave exposure under claims 3–4 unless those claims are not asserted due to product presentation.
- Indication targeting
- Claims are framed for arterial thrombosis prevention/treatment. If a product is positioned differently, litigation focus changes.
Does this patent cover “method of treatment” claims or just composition claims?
Within the provided claim set (1–6), the patent is drafted as:
- Product claims (heparin fragments; pharmaceutical composition containing fragments)
- A therapeutic use statement (“preventative treatment or treatment of arterial thrombosis”) is included in the composition claims.
There is no standalone method-of-treatment claim shown in the provided set. That structure affects enforcement strategy: infringement hinges on whether the accused product is a covered composition intended and/or used for the specified indication, rather than solely on clinical activity.
Orange Book status and FDA exclusivity: what matters for this patent?
No Orange Book listing, FDA approval, reference product, or exclusivity information is provided in the prompt. With only the claim text and without identifying the related FDA product(s), a correct “Orange Book status” analysis cannot be produced.
Key Takeaways
- U.S. Patent 4,303,651 is centered on defined heparin fragment structures rather than a generic LMWH category, using three main structural constraints: (i) 14–18 sugar units, (ii) dominant disaccharide motif (L-iduronosyl-2-O-sulfate–N-sulfo-D-glucosamine-6-O-sulfate), and (iii) positional requirement for an unsulfated L-iduronic acid 3–5 residues from the unreducing terminus with a defined following residue set.
- Claim 2 is a tight structural formula with n = 1 or 2 and m = 5 or 6, yielding four permitted repeat topologies.
- Composition claims (claims 3–4) restrict use to prevention or treatment of arterial thrombosis, with vehicle scope broad in claims 3–4 and narrowed in claims 5–6 to water and ointment respectively.
- For competitive programs, the most direct design-around levers are fragment length, unsulfated iduronic acid placement, and adjacent residue identity/sulfation, followed by formulation presentation to avoid claim 5/6.
FAQs
-
Can a competitor avoid infringement by changing fragment length within heparin fragment mixtures?
Yes, the 14–18 sugar unit limit in claim 1 and claim 3 is a direct constraint; producing fragments outside the window undermines coverage under those claim elements.
-
Does having the same sulfated building blocks (U and G) automatically infringe claim 2?
No. Claim 2 also requires an embedded unsulfated iduronic acid (I) and specific repeat counts via n and m.
-
Is “unsulphated L-iduronic acid” in claim 1 a count requirement or a positional requirement?
It is both functionally constrained by structure: the claim specifies that unsulfated iduronic acid is located 3–5 sugar units from the unreducing terminus and is followed by an allowed residue set.
-
Would changing the dosage form from ointment to gel or solution avoid claim 6?
Yes for claim 6 specifically, because claim 6 limits the composition to an ointment. Other claims (3–4) would still need evaluation.
-
Does the indication “arterial thrombosis” limit enforceability even if the fragment structure matches?
Within the provided set, the therapeutic framing is built into the composition claims; infringement analysis would focus on whether the accused product is within those covered composition claims for that indication.
References (APA)
- United States Patent 4,303,651 (claims 1–6 as provided in prompt).
